Interventions in the management of infection in the foot in diabetes: A systematic review

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue , 2016, Pages 145-153

  Peters, E J ^a   Lipsky, B A ^b,c   Aragon Sanchez J ^d   Boyko, E J ^e   Diggle, M ^f   Embil, J M ^g   Kono, S ^h   Lavery, L A ⁱ   Senneville, E ^j   Urbancic Rovan V ^k   Van Asten, S A ^a,i   Jeffcoate, W J ^f  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d La Paloma Hospital   (Spain)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g UNIVERSITY OF MANITOBA   (Canada)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j Gustave Dron Hospital   (France)

^k UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

more..

Author keywords

Antibiotics; Diabetes mellitus; Diabetic foot infection; Osteomyelitis; Surgery; Systematic review

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; POVIDONE; PROCAINE; TOPICAL ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC FOOT INFECTION; DIABETIC PATIENT; HUMAN; HYPERBARIC OXYGEN; INFECTION; META ANALYSIS; META ANALYSIS (TOPIC); ORTHOPEDIC SURGERY; OSTEOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; COMPLICATION; EVIDENCE BASED MEDICINE; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY; PERSONALIZED MEDICINE; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS;

ANTI-INFECTIVE AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; COMBINED MODALITY THERAPY; DIABETIC FOOT; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOMYELITIS; PRECISION MEDICINE; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS;

EID: 84956827870     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2706     Document Type: Article

References (57)

1. Raspovic KM, Wukich DK. Self-reported quality of life and diabetic foot infections. J Foot Ankle Surg 2014; 53: 716-719.
2. Berendt AR, Peters EJ, Bakker K, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 2008; 24(Suppl 1): S145-S161.
3. Peters EJ, Lipsky BA, Berendt AR, et al. A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot. Diabetes Metab Res Rev 2012; 28(Suppl 1): 142-162.
4. National Institute for Health and Clinical Excellence. Diabetic foot - inpatient management of people with diabetic foot ulcers and infection. http://guidance.nice.org.uk/CG119. 2011.
5. Tan T, Shaw EJ, Siddiqui F, Kandaswamy P, Barry PW, Baker M. Inpatient management of diabetic foot problems: summary of NICE guidance. BMJ 2011; 342: d1280.
6. Byren I, Peters EJ, Hoey C, Berendt A, Lipsky BA. Pharmacotherapy of diabetic foot osteomyelitis. Expert Opin Pharmacother 2009; 10: 3033-3047.
7. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54: e132-e173.
8. Blanes JI. Consensus document on treatment of infections in diabetic foot. Rev Esp Quimioter 2011; 24: 233-262.
9. Société de Pathologie Infectieuse de Langue Française. Management of diabetic foot infections. Long text. Société de Pathologie Infectieuse de Langue Française. Med Mal Infect 2007; 37: 26-50.
10. Dutch Cochrane Centre. http://dcc.cochrane.org/. [article online], 2014.
11. Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook. http://www.sign.ac.uk/pdf/qrg50.pdf. [article online], 2014.
12. Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect 2010; 16: 1252-1257.
13. Viswanathan V, Mahesh U, Jayaraman M, Shina K, Ramachandram A. Beneficial role of granulocyte colony stimulating factor in foot infection in diabetic patients. J Assoc Physicians India 2003; 51: 90-91.
14. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35: 381-389.
15. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34: 1460-1468.
16. Dalla Paola L, Carone A, Ricci S, Russo A, Ceccacci T, Ninkovic S. Use of vacuum assisted closure therapy in the treatment of diabetic foot wounds. J Diabetic Foot Complications 2010; 2: 33-44.
17. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 2008; 47: 1537-1545.
18. Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File TMJ. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 1996; 23: 286-291.
19. Faglia E, Clerici G, Caminiti M, Quarantiello A, Gino M, Morabito A. The role of early surgical debridement and revascularization in patients with diabetes and deep foot space abscess: retrospective review of 106 patients with diabetes. J Foot Ankle Surg 2006; 45: 220-226.
20. Lázaro-Martínez JL, Aragón-Sánchez J, Garcia-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care 2014; 37: 789-795.
21. Ulcay A, Karakas A, Mutluoglu M, Uzun G, Turhan V, Ay H. Antibiotherapy with and without bone debridement in diabetic foot osteomyelitis: a retrospective cohort study. Pak J Med Sci 2014; 30: 28-31.
22. Clay PG, Graham MR, Lindsey CC, Lamp KC, Freeman C, Glaros A. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. Am J Geriatr Pharmacother 2004; 2: 181-189.
23. Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. Am J Health Syst Pharm 2007; 64: 1080-1086.
24. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-1703.
25. Martínez-De Jesús FR, Ramos-De la Medina A, Remes-Troche JM, et al. Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections. Int Wound J 2007; 4: 353-362.
26. Chen W, Xu K, Zhang H, Shang Y, Hao P. A comparative study on effect of bacterial load in diabetic foot ulcers dealing with iodophor and rivanol respectively. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2008; 22: 567-570.
27. Piaggesi A, Goretti C, Mazzurco S, et al. A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. Int J Low Extrem Wounds 2010; 9: 10-15.
28. Landsman A, Blume PA, Jordan DA Jr, Vayser D, Gutierrez A. An open-label, three-arm pilot study of the safety and efficacy of topical Microcyn Rx wound care versus oral levofloxacin versus combined therapy for mild diabetic foot infections. J Am Podiatr Med Assoc 2011; 101: 484-496.
29. Lipsky BA, Kuss M, Edmonds M, Reyzelman A, Sigal F. Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. J Am Podiatr Med Assoc 2012; 102: 223-232.
30. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 855-859.
31. Yönem A, Cakir B, Güler S, Azal OO, Corakçi A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3: 332-337.
32. de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45: 1094-1098.
33. Kästenbauer T, Hörnlein B, Sokol G, Irsigler K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia 2003; 46: 27-30.
34. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Sys Rev3 2013; 8: 1-30. CD006810. DOI: 10.1002/14651858.CD006810.pub3.
35. Duarte HA, Fernandez Montequin JI, Fors Lopez MM, Carretero JH, Vilas MM, Mesa MG. Clinical evaluation of de Marco formula as an adjunctive therapy for infected ischemic diabetic foot: a prospective randomized controlled trial. Can J Clin Pharmacol 2009; 16: e381-e391.
36. Mesa MG, Duarte HA, Carretero JH, Lopez MM, Vilas MM. De Marco Formula effectiveness as an adjunctive therapy to prevent infected ischemic diabetic foot amputation and reduce plasma fibrinogen. J Tissue Viability 2011; 20: 67-72.
37. Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med 1992; 38: 112-4, 111.
38. Lipsky BA, Peters EJ, Senneville E, et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev 2012; 28(Suppl 1): 163-178.
39. Bansal E, Garg A, Bhatia S, Attri AK, Chander J. Spectrum of microbial flora in diabetic foot ulcers. Indian J Pathol Microbiol 2008; 51: 204-208.
40. El-Tahawy AT. Bacteriology of diabetic foot. Saudi Med J 2000; 21: 344-347.
41. Viswanathan V, Jasmine JJ, Snehalatha C, Ramachandran A. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India 2002; 50: 1013-1016.
42. Bradsher RW Jr, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med 1984; 77: 63-67.
43. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990; 150: 790-797.
44. Siami G, Christou N, Eiseman I, Tack KJ. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 2001; 45: 525-531.
45. Lobmann R, Ambrosch A, Seewald M, et al. Antibiotic therapy for diabetic foot infections: comparison of cephalosporines with chinolones. Diabetes Nutr Metab 2004; 17: 156-162.
46. Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt) 2005; 6: 27-40.
47. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005; 55: 240-245.
48. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647-655.
49. Vick-Fragoso R, Hernandez-Oliva G, Cruz-Alcazar J, et al. STIC Study Group: efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection 2009; 37: 407-417.
50. Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection 2013; 41: 175-186.
51. Lauf L, Ozsvar Z, Mitha I, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis 2014; 78: 469-480.
52. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 2008; 31: 637-642.
53. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-693.
54. Erstad BL, McIntyre J. Prospective, randomized comparison of ampicillin/sulbactam and cefoxitin for diabetic foot infections. Vasc Surg 1997; 31: 419-426.
55. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 1997; 24: 643-648.
56. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.
57. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 2007; 60: 370-376.